Journal
SUBSTANCE ABUSE
Volume 33, Issue 1, Pages 48-59Publisher
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/08897077.2011.609438
Keywords
Extended-release naltrexone; opioid dependence; Depotrex; addiction pharmacotherapy; offenders; heroin
Categories
Funding
- National Institute on Drug Abuse [R01-DA-012268-05]
- Dana foundation
Ask authors/readers for more resources
A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available